Journal of Neuroimmune Pharmacology
Published/Hosted by Springer.
ISSN (printed): 1557-1890. ISSN (electronic): 1557-1904.
The Journal of Neuroimmune Pharmacology (JNIP) is the peer-reviewed journal of the Society on NeuroImmune Pharmacology. JNIP interfaces the disciplines of immunology, pharmacology and experimental neuroscience by acting as a platform for research discoveries into the pathogenesis and pharmacology of brain disorders affecting the immune system. Original and interdisciplinary scientific contributions, concise "opinion," and broader reviews are welcome. Research areas reporting in JNIP intersect the disciplines of receptor cell signaling, drugs of abuse, neurodegenerative disorders, neurovirology, immunology, and neuropharmacology. Manuscripts must include original research germane to the immunology and pharmacology of human neurologic and neuropsychiatric disorders including substance abuse, depression, psychosis, Alzheimers and Parkinsons disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, HIV-1 associated dementia, neuroendocrine and microbial infections, and immunological disorders of the brain, spinal cord, and peripheral nerves. Topical studies of brain-immune interactions include, but are not limited to: (1) leukocyte trafficking into the nervous system and immune surveillance; (2) innate immunity in the nervous system; (3) pathophysiology of neurodegenerative diseases; (4) effects of drugs of abuse and cognate endogenous ligands on brain-immune interactions (neuronal-peripheral immune; neuronal-glial); (5) implications of the effects of drugs of abuse, endogenous ligands and other pharmacophores on peripheral immune responses, and (6) medicinal chemistry and drug development and vaccine approaches for neurologic and neuropsychiatric diseases. JNIP will identify novel pharmacologic discoveries (organized action of drug targets, mechanisms, and development) of brain-immune interactions with a potential towards modifying the cellular and systemic responses that affect disease or lead to amelioration of brain injury and immune dysfunction.
- Further information
- Category Links